Clinical reference Biomarker Directory
Back to directory

C-terminal telopeptide

Established

CTX is a bone resorption marker used to monitor osteoporosis treatment and estimate jaw osteonecrosis risk.

Also known as CTX CTx collagen telopeptide crosslaps
In plain language

CTX shows how quickly old bone is being broken down. It helps track osteoporosis treatment, and dentists sometimes use it to gauge jaw-bone risk before extractions in patients on long-term bone-strengthening drugs — though this particular use is still debated since it isn't perfectly reliable.

Biomarker & context

C-terminal telopeptide (CTX) of type I collagen is a breakdown product released during bone resorption (the process by which old bone is broken down), serving as a marker of bone turnover rate.

What it indicates

CTX levels reflect the intensity of bone resorption, used to monitor osteoporosis treatment response, and — more distinctively — to help estimate a patient's risk of medication-related osteonecrosis of the jaw (MRONJ) before invasive dental procedures in patients on long-term bisphosphonates.

Diagnosis & clinical testing

Measured via serum immunoassay; proposed MRONJ risk bands are <100 pg/mL (high risk), 100–150 (moderate), >150 (minimal risk), though this application remains genuinely controversial — studies have found patients with "safe" high CTX levels who still developed osteonecrosis, and vice versa.

Guiding treatment

A drop of at least 25% in CTX from baseline after 3-6 months indicates adequate bisphosphonate treatment response; a "drug holiday" (temporary bisphosphonate pause) before invasive dental work is sometimes guided by CTX levels, alongside clinical judgment.

Clinical significance

Its use for predicting individual osteonecrosis risk before dental surgery remains scientifically debated.

References
  1. JCDA. C-Terminal Cross-Linking Telopeptide as a Serologic Marker for Bisphosphonate-Related Osteonecrosis of the Jaw.
  2. Cleveland Clinic Journal of Medicine. (2023). Making best use of bone turnover markers to monitor oral bisphosphonate therapy.